Six investment themes built over 18 years of focused healthcare investing — each backed by deep domain knowledge, proprietary networks, and a consistent track record of value creation.
Early to late-stage investments in novel therapeutics, precision medicine platforms, and next-generation drug delivery systems addressing critical unmet medical needs.
We look for companies with novel mechanisms of action, defensible IP estates, strong clinical leadership teams, and clear regulatory pathways in large addressable markets.
AI-powered diagnostics, health data platforms, and patient engagement technologies that are redefining care delivery at scale and generating measurable clinical outcomes.
We favour companies with proprietary data assets, network effects, and deep clinical validation. Pure software plays without clinical evidence rarely meet our investment bar.
Strategic capital for breakthrough medical device and diagnostics companies — from early prototype through regulatory clearance and into global commercial scale across multiple markets.
We bring deep expertise in FDA 510(k) and PMA pathways, CE marking, and international reimbursement strategy. Commercial model clarity is a prerequisite for our investment.
Growth equity and buyout investments in healthcare services businesses and enterprise health technology platforms — combining delivery model innovation with the infrastructure modernising clinical workflows, operations, and patient engagement at scale.
We look for operational improvement potential, technology integration roadmaps, scalable SaaS models with enterprise contract visibility, and payer relationship strength across both services and tech plays.
Funding the pioneers in gene therapy, CRISPR-based medicine, cell therapy, and synthetic biology platforms transforming patient outcomes at scale across rare and common diseases.
We invest in the full genomics stack — from platform technologies and manufacturing infrastructure to clinical-stage programs with validated proof-of-concept data.
Facilitating high-value alliances between growth-stage healthcare companies and global pharma, institutional investors, and strategic acquirers to unlock transformational value creation.
We leverage 18 years of C-suite relationships and institutional investor networks to structure transactions that align incentives and create durable strategic value for all parties.